Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab

Modern Rheumatology

Volumn 21, Issue 4, 2011, Pages 420-422

  Nishida, Sumiyuki ^a   Kawasaki, Tomio ^a   Kashiwagi, Hirokazu ^a   Morishima, Atsuyoshi ^a   Hishitani, Yoshihiro ^a   Kawai, Mari ^a   Hirano, Toru ^a   Ishii, Taeko ^a   Hagihara, Keisuke ^a   Shima, Yoshihito ^a   Narazaki, Masashi ^a   Ogata, Atsushi ^a   Oka, Yoshihiro ^a   Kishimoto, Tadamitsu ^b   Tanaka, Toshio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Acquired hemophilia A; Factor VIII; IL 6; Inhibitors; Tocilizumab

Indexed keywords

AMPICILLIN; BLOOD CLOTTING FACTOR 8; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TOCILIZUMAB;

AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG MECHANISM; FEMALE; GLAUCOMA; HEMOPHILIA A; HUMAN; IMMUNOGLOBULIN DEFICIENCY; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PURPURA; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG THERAPY, COMBINATION; FACTOR VIII; FEMALE; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMOPHILIA A; HUMANS; PREDNISOLONE; TREATMENT OUTCOME;

EID: 83255170953     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0411-6     Document Type: Article

References (13)

1. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008;112:250-5.
2. Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol. 2009;148:183-94.
3. Toschi V, Baudo F. Diagnosis, laboratory aspects and management of acquired hemophilia A. Intern Emerg Med. 2010;5:325-33.
4. Reding MT. Immunological aspects of inhibitor development. Haemophilia. 2006;12(Suppl 6):30-5.
5. Huth-Kuhne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Leveque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94:566-75.
6. Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2010;6: 843-54.
7. Levesque M, St-Clair EW. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol. 2008;212:13-21.
8. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 2007;110:3804-13. (Pubitemid 350159652)
9. Radojcic V, Pletneva MA, Yen HR, Ivceviv S, Panoskaltsis- Mortari A, Gilliam AC, et al. STAT3 signaling in CD4? T cells is critical for the pathogenesis of chronic sclerodermatous graftversus- host-disease in a murine model. J Immunol. 2010;184: 764-74.
10. Mihara M, Ohsugi Y, Kishimoto T. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by antiinterleukin- 6 receptor antibody. Biofactors. 2009;35:47-51.
11. Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versushost disease. Blood. 2009;114:891-900.
12. Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R, et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res. 2010 (Epub ahead of print).
13. Gergis U, Arnason J, Yantiss R, Shore T, Wissa U, Feldman E, et al. Effectiveness and safety of tocilizumab, an anti-interleukin- 6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. J Clin Oncol. 2010;28:602-4.